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Background
Glatiramer acetate (GA) is immunomodulatory drug
widely prescribed for the treatment of multiple sclerosis
(MS). GA treatment is frequently associated with local
site reactions and generalized urticaria. The systemic
reaction approximately occurs in 10% of patients. The
desensitization could help to return GA to MS treatment.
Objective
Our aim was to evaluate the safety and efficiency of GA
desensitisation. Eight days of the GA treatment MS female
patient came with adverse reactions. Twelve hours after
GA administration itching in the injection site, feeling of
swelling tongue, swallowing difficulty and cough appeared.
Methods
The 38-year-old woman with a diagnosis of MS was
examined from April until July 2013 at the Allergology
Unit, Department of Internal Medicine and Gastroenter-
ology. In the absence of specific IgE tests against GA, a
basophil activation test (BAT) was performed with a
borderline result (GA concentration 1.0 ul/ml with 7.8%
activated basophils, stimulation index 2.1). Then fol-
lowed the GA skin tests with a positive results (skin
prick test was negative, i.d. dilution 1:100 and 1:10 were
positive (6 and 7.6mm weal diameter). Finally, on 11th
July, 2013, after written informed patient consent, a
4-hour outpatient GA desensitisation procedure was
carried out. Beginning with 20ng, we administered sub-
cutaneous GA suspension in increasing dosage every
30 minutes to the target dose of 20 mg GA. Patients
outcomes were monitored by return visit and by tele-
phone follow-up.
Results
No episodes of anaphylaxis or other adverse reaction
occurred during or immediately after desensitisation.
Our patient was able to successfully continue GA ther-
apy (20 mg GA s.c. daily).
Conclusions
In MS patients with adverse local or systemic reactions
to GA, desensitization can be a solution allowing the
return of GA treatment and improve the course of MS
disease.
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